Quick answers
- What is Citalopram used for?
- The FDA-approved label (Celexa, Allergan, Inc., October 9, 2023) says: “CELEXA is indicated for the treatment of major depressive disorder (MDD) in adults […]. CELEXA is a selective serotonin reuptake inhibitor (SSRI) indicated for the treatment of major depressive disorder (MDD) in adults.” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- Does Citalopram have a boxed warning?
- Yes. The FDA label for Celexa has a boxed warning (“WARNING: SUICIDAL THOUGHTS AND BEHAVIORS”), the FDA’s strongest warning. Read it on the full label and ask your pharmacist.
- Is there a shortage of Citalopram?
- No current shortage is listed by the FDA for the products of this medicine (FDA data from October 30, 2026).
- Has Citalopram been recalled?
- FDA enforcement reports list 1 recall of products of this medicine; the newest started January 26, 2022 (Class II). A recall usually concerns specific lots, not every product.
- Who makes Citalopram?
- 35 companies list prescription products of Citalopram in the FDA NDC Directory, including A-S Medication Solutions, Remedyrepack Inc. and NuCare Pharmaceuticals, Inc..
What Citalopram is used for
Quoted from the “Indications and Usage” section of the FDA-approved label.
CELEXA is indicated for the treatment of major depressive disorder (MDD) in adults […]. CELEXA is a selective serotonin reuptake inhibitor (SSRI) indicated for the treatment of major depressive disorder (MDD) in adults.
— FDA label: Celexa, Allergan, Inc., effective October 9, 2023. Read the full label on DailyMed →
The FDA has 86 labels for products of this medicine (different makers and forms); uses can differ between them. Check the label that comes with your own medicine.
This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Conditions named on the label
These condition names appear word for word in the label’s “Indications and Usage” text (matched with a reviewed table). Each page lists hospitals whose own websites name the condition.
Related medical specialties
Boxed warning
A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.
This label has a boxed warning. Its heading: WARNING: SUICIDAL THOUGHTS AND BEHAVIORS
. Read it on the full label →
86 of 86 FDA labels for this medicine have a boxed warning.
Forms and how it is given
| Dosage forms | Tablet, film coated · Tablet · Solution · Capsule |
|---|---|
| Route | Oral |
| Prescription products | 117 in the FDA NDC Directory |
| Brand names | Celexa |
What pharmacies pay (NADAC)
The National Average Drug Acquisition Cost (NADAC) is the average price U.S. retail pharmacies paid to buy one unit of a medicine (one tablet, one mL or one gram), from a monthly survey of pharmacy invoices by the Centers for Medicare & Medicaid Services (CMS). State Medicaid programs use it to pay pharmacies.
This is not the price you pay. What you pay depends on your insurance (copay or coinsurance), your pharmacy and any discounts, and pharmacies also charge for filling a prescription. Ask your pharmacist or your health plan what your price will be.
| Strength and form | Generic or brand | Pharmacies pay |
|---|---|---|
| citalopram hydrobromide 10 mg tablet | Generic | $0.0286 per tablet |
| citalopram hydrobromide 10 mg tablet, film coated | Generic | $0.0286 per tablet |
| citalopram hydrobromide 10 mg/5 mL solution | Generic | $0.1929 per mL |
| citalopram hydrobromide 20 mg tablet | Generic | $0.0303 per tablet |
| citalopram hydrobromide 20 mg tablet, film coated | Generic | $0.0303 per tablet |
| citalopram hydrobromide 20 mg tablet, film coated | Brand: Celexa | $9.04 per tablet |
| citalopram hydrobromide 30 mg capsule | Generic | $4.74 per capsule |
| citalopram hydrobromide 40 mg tablet | Generic | $0.0416 per tablet |
| citalopram hydrobromide 40 mg tablet, film coated | Generic | $0.0416 per tablet |
| citalopram hydrobromide 40 mg tablet, film coated | Brand: Celexa | $9.47 per tablet |
NADAC list of November 4, 2026; these prices took effect on October 21, 2026. Shown only where a package’s NDC code matches the NADAC list exactly, and only for that exact strength and form: nothing is averaged across strengths. Strengths and forms not listed here have no NADAC price.
Source: NADAC (National Average Drug Acquisition Cost) 2026, data.medicaid.gov (CMS) →
Companies that list this medicine
Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.
- A-S Medication Solutions10 products
- Remedyrepack Inc.9 products
- NuCare Pharmaceuticals, Inc.8 products
- Northwind Health Company, LLC8 products
- Bryant Ranch Prepack6 products
- PD-Rx Pharmaceuticals, Inc.5 products
- Proficient Rx LP5 products
- Aurobindo Pharma Limited5 products
- Aphena Pharma Solutions - Tennessee, LLC5 products
- Allergan, Inc.3 products
- NCS HealthCare of KY, LLC dba Vangard Labs3 products
- Quallent Pharmaceuticals Health LLC3 products
- Asclemed USA, Inc.3 products
- Amneal Pharmaceuticals LLC3 products
- Coupler LLC3 products
- Torrent Pharmaceuticals Limited3 products
- Exelan Pharmaceuticals Inc.3 products
- Epic Pharma, LLC3 products
- Preferred Pharmaceuticals Inc.3 products
- Mylan Pharmaceuticals Inc.3 products
- Cipla USA Inc.3 products
- Major Pharmaceuticals2 products
- Quality Care Products, LLC2 products
- St. Mary's Medical Park Pharmacy2 products
- QPharma, Inc.2 products
- Cardinal Health 107, LLC2 products
- Advanced Rx of Tennessee, LLC2 products
- Chartwell RX, LLC1 product
- Chartwell Governmental & Specialty RX, LLC.1 product
- Atlantic Biologicals Corp.1 product
- Hikma Pharmaceuticals USA Inc.1 product
- Advanced Rx Pharmacy of Tennessee, LLC1 product
- Camber Pharmaceuticals, Inc.1 product
- Almatica Pharma LLC1 product
- Golden State Medical Supply, Inc.1 product
FDA approval history
- NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
- ANDA: Abbreviated New Drug Application: how a generic version is approved.
| Application | Sponsor | Approved | Later changes approved |
|---|---|---|---|
| NDA020822 CELEXA | Abbvie | July 17, 1998 | 33, latest April 19, 2024 2024: Labeling · 2023: Labeling · 2022: Labeling |
| NDA215428 CITALOPRAM HYDROBROMIDE | Almatica | January 31, 2022 | 1, latest August 18, 2023 2023: Labeling |
Generic approvals (11)
- ANDA077031Aurobindo · October 28, 2004
- ANDA077042Mylan · November 5, 2004
- ANDA077043Hikma · December 13, 2004
- ANDA077045Epic Pharma · April 29, 2005
- ANDA077629Chartwell Molecular · June 14, 2006
- ANDA077812Aurobindo Pharma · August 28, 2006
- ANDA077534Invagen Pharms · October 3, 2006
- ANDA077289Amneal Pharms Ny · November 30, 2006
- ANDA078216Torrent Pharms · March 27, 2007
- ANDA201450Hetero Labs Ltd III · December 15, 2015
- ANDA219985Aurobindo Pharma Ltd · March 13, 2026
Shortage status
The FDA drug shortage list does not show these products.
Recalls
From FDA enforcement reports, matched by the product’s NDC code. A recall usually covers specific lots only: check the lot number on your package and ask your pharmacist. Do not stop a medicine on your own.
-
January 26, 2022 · Class II · Terminated · D-0173-2024
CGMP Deviations: Products were exposed to temperatures outside of the products labeled storage conditions.
CITALOPRAM Tablets, USP, 20MG, 100 Tablets, Rx only, Manufactured for: Mylan Pharmaceuticals Inc., Morgantown, WV 26505 USA. NDC: 0378-6232-01 — CARDINAL HEALTHCARE
What do the recall classes mean?
Class I: The most serious type: there is a reasonable chance that using the product will cause serious health problems or death.
Class II: Using the product may cause temporary or medically reversible health problems, or the chance of serious problems is remote.
Class III: Using the product is not likely to cause health problems (for example a labeling or packaging issue).
Official identifiers
Sources
- FDA-approved label on DailyMed (National Library of Medicine) — Celexa, Allergan, Inc., effective October 9, 2023; via openFDA, FDA data exported October 30, 2026, retrieved October 31, 2026
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
- Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →